[Unknown type: UNSPECIFIED]
Abstract
Rationale: The COVID-19 pandemic has led to more than 445,000 deaths worldwide. There is an urgent need for effective treatment. Studies suggest that a hyper-inflammatory response is a major cause of disease severity and death. Using precision medicine to rapidly identify patients with COVID-19 with hyper-inflammation may be key for identify subgroups who may benefit from targeted immunomodulatory treatments.
Methods: In combination with a diagnostic point-of-care test (POCT), we used a rapid multiplex cytokine assay to measure serum IL-6, IL-8, TNF-α, IL-1β, GM-CSF, IL-10, IL-33 and IFN-γ in 101 hospitalised patients with confirmed COVID-19 at admission to University Hospital Southampton. Demographic, clinical, laboratory and outcome data were collected for all patients.
Findings: Age over 70 years was the strongest predictor of death (OR 28, 95% CI 5.94, 139.45). Cytokines IL-6, IL-8, TNF-α, IL-1β and IL-33 were significantly associated with adverse outcome in COVID-19. Clinical parameters at admission were predictive of poor outcome (AUROC 0.71), with addition of a combined cytokine panel significantly improving the predictability (AUROC 0.85). In those < 70 years, IL-33 and TNF-α were predictive of poor outcome (AUROC 0.84 and 0.83), and addition of a combined cytokine panel demonstrated greater predictability of poor outcome than clinical parameters alone (AUROC 0.92 vs 0.77).
Interpretation: A combined cytokine panel improves the accuracy of the predictive value for adverse outcome beyond standard clinical data alone. Rapid identification of specific cytokines may help to stratify patients towards trials of specific immunomodulatory treatments to improve outcomes in COVID-19.
This record has no associated files available for download.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.